[Bioequivalence of an optimized doxycycline preparation]

Area of Science:

• Pharmacology
• Pharmaceutical Sciences
• Drug Bioavailability Studies

Background:

• Doxycycline is a widely used antibiotic.
• Ensuring consistent bioavailability and bioequivalence of pharmaceutical preparations is crucial for therapeutic efficacy.
• New regulatory criteria necessitate rigorous testing of doxycycline products.

Purpose of the Study:

• To compare the bioavailability and bioequivalence of Sigadoxin, a novel doxycycline preparation, against a reference doxycycline product.
• To evaluate Sigadoxin according to the latest guidelines from the Central Laboratory of German Pharmacists.

Main Methods:

• A comparative study design was employed.
• Key pharmacokinetic parameters, including Area Under the Curve (AUC) and maximum concentration (Cmax), were measured.
• Urinary excretion rates were analyzed to assess drug disposition.
• Statistical evaluation was performed based on the new "Criteria for testing of the bioavailability and bioequivalence of doxycycline-containing products".

Main Results:

• The trial preparation (Sigadoxin) showed an AUC of 44.9 mg/l and Cmax of 2.87 mg/l.
• The reference preparation exhibited an AUC of 50.3 mg/l and Cmax of 3.19 mg/l.
• Relative bioavailability of Sigadoxin, based on AUC, was determined to be 89.3%.

Conclusions:

• Sigadoxin demonstrated comparable bioavailability to the reference doxycycline preparation.
• The results indicate that Sigadoxin can be considered bioequivalent to the reference product.
• The study confirms the pharmaceutical quality and therapeutic equivalence of the Sigadoxin formulation.